Comprehensive Analysis of Somatic Mutations in Colorectal Cancer With Peritoneal Metastasis

Abstract

Background: To analyze for genetic mutations which may presage peritoneal metastasis by using targeted next-generation sequencing (NGS). Materials and Methods: Formalin-fixed, paraffin-embedded primary tumor specimens were obtained from 10 patients with small obstructing colorectal cancer and peritoneal metastasis (group A) and five with large non-obstructing colorectal cancer and no recurrence (group B). DNA was extracted for the sequencing of 409 cancer genes. The distribution of genetic mutations was compared between the two groups to find genetic mutations related to peritoneal metastasis. Results: When the samples were sorted based on similarity of gene expression by hierarchical clustering analysis, the samples were well divided between the two study groups. Mutations in ATrich interactive domain-containing protein 1A (ARID1A), polycystic kidney and hepatic disease 1 (PKHD1), ubiquitin-protein ligase E3 component n-recognin 5 (UBR5), paired box 5 (PAX5), tumor protein p53 (TP53), additional sex combs like 1 (ASXL1) and androgen receptor (AR) genes were detected more frequently in group A. Conclusion: A number of somatic mutations presumed to be relevant to colorectal cancer with peritoneal metastasis were identified in our study by NGS. 447This article is freely accessible online.

Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer

“…The implantation of tumor cells in the abdominal cavity can be caused by the flow of blood and lymph into the abdominal cavity by the severed blood vessels and lymphangioma embolus, the pulling and squeezing of tumor tissues during the operation, or the inflow of tumor cells through the intestinal stump with intestinal fluid. Patients with peritoneal metastasis had a worse prognosis than those without, and the higher the degree of peritoneal metastasis, the shorter the survival time [ 34 , 35 ]. The addition of simvastatin is not a factor affecting the mean survival time of CRC patients, but it can prolong the overall survival time of patients within 3–5 years, and it is expected to be used as a routine drug regimen to optimize the prognosis of CRC patients.…”

Identification of Hub Genes Related to Carcinogenesis and Prognosis in Colorectal Cancer Based on Integrated Bioinformatics

“…Mediators of Inflammation database and firstly proposed as an independent prognostic factor (Table S14). PAX5 was identified to be relevant to CRC with peritoneal metastasis [77].…”

LINC00586 Represses ASXL1 Expression Thus Inducing Epithelial-To-Mesenchymal Transition of Colorectal Cancer Cells Through LSD1-Mediated H3K4me2 Demethylation

“…Subsequently, mechanistic investigation showed that LINC00586 knockdown upregulated ASXL1 expression, whereas ectopic expression of LINC00586 downregulated ASXL1 expression in CRC cells. Aberrantly expressed ASXL1 has also been identified in CRC previously ( Lee et al, 2019 ). However, we were the first reporting the regulatory relationship between LINC00586 and ASXL1.…”